However, IDO1 inhibitor monotherapies did not show the expected efficacy, whereas the combination with immunotherapeutic approaches showed negative results in phase-III clinical trials [67], indicating that further studies are needed for the effective targeting of IDO in cancer. The gene discussed is IDO1; the disease is cancer.